Premium
Lymphomatoid papulosis type A: clinical, morphologic, and immunophenotypic study
Author(s) -
Sioutos Nicholas,
Asvesti Catherine,
Sivridis Efthimios,
Aygerinou Georgia,
Tsega Artemis,
Zakopoulou Nikoletta,
Zographakis Ioannis
Publication year - 1997
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.1997.00081.x
Subject(s) - lymphomatoid papulosis , medicine , pathology , cd30 , lymphoproliferative disorders , anaplastic large cell lymphoma , cd15 , lymphoma , pseudolymphoma , dermatology , cd34 , stem cell , biology , genetics
Background Lymphomatoid papulosis (LyP) is a cutaneous clonal or polyclonal Ki‐1 + T‐cell lymphoproliferative disorder, morphologically resembling Ki‐1 + anaplastic large cell lymphomas (Ki‐1 + ALCL) or Hodgkin's disease (HD). Lymphomatoid papulosis usually has a characteristic benign clinical course with remissions and relapses of the cutaneous eruptions. Methods The authors studied three patients with LyP. in each case the diagnosis was established based on the typical clinical history and presentation of the cutaneous lesions as well as the morphologic and immunophenotypic findings. Results in all three cases the skin biopsies showed a polymorphic, nonepidermotropic, dermal lymphocytic infiltrate, composed of small lymphocytes and fewer large, atypical cells. The large ceils were positive for the activation markers CD30 (Ki‐1) and CD45R (leukocyte common antigen), and were negative for the HD marker CD15 (Leu Ml). Conclusions In most cases, LyP can be distinguished from Ki‐1 + ALCL and HD on the basis of clinical, morphologic, and/or immunophenotypic findings. We emphasize the importance of the recognition of LyP as a clinicopathologic entity and the awareness of dermatologists, oncoiogists, and surgical pathologists in differentiating LyP from other primary cutaneous Ki‐1 + lymphoproliferative disorders (Ki‐1 + ALCL and HD). The prognosis of cutaneous Ki‐1 + ALCL and HD is usually different from LyP and requires a different therapeutic approach.